Feb. 14 – New amendments arranged by the Federal Antimonopoly Service (FAS) may release overseas pharmaceuticals backed by suitable foreign trials from re-examination in Russia.
The FAS also suggests calling off a five-year validity of drug registration certificates, Head of the Department for Control over Social Sphere and Trade of FAS Timofey Nizhegorodtsev said at the sidelines of the conference “Pharmaceutical Business in Russia: Times of Change.” FAS amendments were following the watch dog’s inspection of the drug registration procedure of the Ministry of Health Care and Social Development. Read the rest of this entry »







